Clinical Trial Update: Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe

View source ↗

Summary

Post-marketing surveillance study to observe safety and efficacy of Xyntha Solofuse Prefilled Syringe has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Hemophilia
• Classic Hemophilia
• Factor 8 Deficiency Congenital
• Factor Viii Deficiency Congenital
• Hemophilia Congenital

Drugs mentioned

• Xyntha Solofuse Prefilled Syringe

Snippet

Sponsor: Pfizer | Conditions: Factor VIII Deficiency, Congenital, Factor 8 Deficiency, Congenital | Status: COMPLETED | Results posted: 2019-04-05